Response to “Determinants of Ultra‐Long‐Term Survival in Multiple Myeloma: A Critical Appraisal of Foundational Assumptions and a Call for Biologically Driven Inquiry”

Documenti analoghi

• Evaluating Minimal Residual Disease Negativity as a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta‐Analysis of Randomized Controlled Trials
  di: Ioannis Ntanasis‐Stathopoulos, et al.
  Pubblicazione: (2025)
• The Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma With Renal Impairment: A Systematic Review
  di: Ioannis Ntanasis‐Stathopoulos, et al.
  Pubblicazione: (2026)
• Determinants of 15‐Year Progression‐Free Survival in Multiple Myeloma; Real‐World Data From a Single Institution
  di: Meletios A. Dimopoulos, et al.
  Pubblicazione: (2025)
• Response to Methodological Concerns Regarding Eligibility Criteria and Study Selection in a Systematic Review and Meta‐Analysis of CAR T‐Cell Therapy for Hematologic Malignancies
  di: Charalampos Filippatos, et al.
  Pubblicazione: (2026)
• Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA
  di: Evangelos Terpos, et al.
  Pubblicazione: (2024)